{"url_path":"/sec/tenx/8-k/2026-07-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-293485-index.html","accession_number":"0001193125-26-293485","cik":"0000034956","ticker":"TENX","issuer_name":"TENAX THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-293485-index.html","primary_entity_key":"0000034956","primary_entity_name":"TENAX THERAPEUTICS, INC."},"word_count":75,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nOn July 2, 2026, Tenax Therapeutics, Inc. (the “Company”) issued a press release announcing that it will present results from its Phase 3 LEVEL clinical trial in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026. The Company now expects to report topline data from the Phase 3 LEVEL clinical trial in August 2026. A copy of the press release is attached hereto as Exhibit 99.1."}